PA
SLNO

Perceptive Advisors’s Soleno Therapeutics SLNO Stock Holding History

Perceptive Advisors’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-430,439
Closed -$36.1M – 102
2025
Q2 		$36.1M Sell
430,439
-1,076,163
-71% -$80.5M 1.34% 20
2025
Q1 		$108M Buy
1,506,602
+5,562
+0.4% +$271K 3.8% 7
2024
Q4 		$67.5M Sell
1,501,040
-1,703,936
-53% -$88.3M 1.86% 14
2024
Q3 		$162M Hold
3,204,976
– – 3.42% 8
2024
Q2 		$131M Buy
3,204,976
+130,434
+4% +$5.53M 3.15% 8
2024
Q1 		$132M Hold
3,074,542
– – 2.3% 11
2023
Q4 		$124M Hold
3,074,542
– – 2.76% 7
2023
Q3 		$90.7M Buy
3,074,542
+866,789
+39% +$5.25M 3.03% 6
2023
Q2 		$9.47M Buy
+2,207,753
New +$9.49M 0.27% 65

Other funds holding SLNO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Perceptive Advisors's SLNO Position: Q3 2025 in Review

Perceptive Advisors sold out of Soleno Therapeutics (SLNO) in Q3 2025, closing a stake of 430,439 shares — an estimated $36.1M sold.

Perceptive Advisors first reported a position in SLNO in Q2 2023 and held it in 9 quarters. The position peaked at $162M in Q3 2024. 240 funds tracked by Wall St. Rank hold SLNO as of Q3 2025.

  • Perceptive Advisors reported no remaining Soleno Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Perceptive Advisors sold 430,439 Soleno Therapeutics shares in Q3 2025, an estimated $36.1M.
  • Perceptive Advisors first reported a position in Soleno Therapeutics in Q2 2023 and held it in 9 quarters.
  • Perceptive Advisors's Soleno Therapeutics position peaked at $162M in Q3 2024.
  • 240 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2025.

Based on Perceptive Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.